

7^a REUNIÓN DE HEPATOLOGÍA TRASLACIONAL

Contribución de las enfermedades hepáticas
y del microambiente al cáncer de hígado



PAMPLONA
23 y 24
octubre 2025

DIRECTORAS

Silvia Affó (Barcelona)
María Arechederra (Pamplona)
María Varela (Oviedo)



PONENTES / MODERADORES

Vanesa Abon (Madrid)	Sandra Hervás (Pamplona)
Silvia Affó (Barcelona)	Josep María Llovet (Barcelona)
María Arechederra (Pamplona)	David Martí-Aguado (Valencia)
Josep María Argemí (Pamplona)	María Luz Martínez Chantar (Bilbao)
Patricia Aspichueta (Bilbao)	Paula Otero (Santiago de Compostela)
Matías Ávila (Pamplona)	María Jesús Perugorria (San Sebastián)
Rafael Bañares (Madrid)	Pedro Rodrigues (San Sebastián)
Elisabeth Baucells (Barcelona)	Alba Rodríguez García (Barcelona)
Carmen Berasain (Pamplona)	Rocío Rodríguez Macías (Salamanca)
Mercedes Fernández (Barcelona)	Sergio Rodríguez-Reynoso (Zaragoza)
María Jesús Fernández (Madrid)	Félix Royo (Bilbao)
Bárbara Fontanals (Barcelona)	Pau Sancho-Bru (Barcelona)
María Antonia Fortuño (Pamplona)	Marco Sanduzzi-Zamparelli (Barcelona)
Rubén Francés (Alicante)	Javier Vaquero (Salamanca)
Rocío Gallego (Sevilla)	María Varela (Oviedo)
Maite García Fernández-Barrena (Pamplona)	Jessica Zucman-Rossi (París)
Antonio Guerrero (Madrid)	



Universidad
de Navarra

IT SERVICES

Instrucciones para acceder a nuestra **red WiFi** **unav-guest**



Diríjase a **Ajustes**



Wi-Fi



Busque y seleccione la **Red:**
unav-guest



Diríjase al **Navegador Web**



Escriba la **URL**

AA

<https://guest.unav.es/login>



Introduzca: **Nombre de usuario**
y **Contraseña**



Diríjase a **Ajustes**



Wi-Fi



Busque y seleccione la **Red:**
unav-guest



Diríjase al **Navegador Web**



Escriba la **URL**

<https://guest.unav.es/login>



Introduzca: **Nombre de usuario**
y **Contraseña**

Usuario

hepatologia

Contraseña

hepatologia25

Puede contactar con Atención Informática en el Tel: 948 425 600, ext: 802992.

10.00 - 11.00 ENTREGA DE DOCUMENTACIÓN

11.00 - 11.15 BIENVENIDA A LA REUNIÓN

Silvia Affó (Barcelona)
María Arechederra (Pamplona)
María Varela (Oviedo)

11.15 - 12.00 KEYNOTE LECTURE (I)

Moderador:

Matías Ávila (Pamplona)

Nuevos paradigmas en cáncer hepático: de la genética a la clínica
Jessica Zucman-Rossi (París)

12.00 - 13.55 SESIÓN 1. ENFERMEDAD HEPÁTICA CRÓNICA COMO FACTOR
DE RIESGO PARA EL DESARROLLO DEL CÁNCER HEPÁTICO

Moderadores:

Rocío Rodríguez Macías (Salamanca)

Pau Sancho-Bru (Barcelona)

12.00 - 12.20 Magnitud y asociación de la enfermedad hepática crónica
y el cáncer hepático

David Martí-Aguado (Valencia)

12.20 - 12.40 Mecanismos y modelos de la enfermedad hepática
crónica por alcohol

Pau Sancho-Bru (Barcelona)

12.40 - 13.00 De la esteatosis hepática metabólica (MASLD)
al cáncer hepático

Patricia Aspichueta (Bilbao)

13.00 - 13.20 De las infecciones virales al cáncer hepático

Paula Otero (Santiago de Compostela)

13.20 - 13.40 De la colestasis al cáncer hepático

Rocío Rodríguez Macías (Salamanca)

13.40 - 13.55

COMUNICACIÓN ORAL SELECCIONADA

Classification of patients with MASH according to serum lipidome identifies DNA damage as a key pathogenic mechanism in a specific subtype

Idoia Fernandez-Puertas (1) | Unai Garzon-Bastera (1) | Ibon Martínez-Arranz (2) | Xabier Buque (1) | Cristina Alonso (2) | Estibaliz Castillero (1) | Ane Ortiz-Palma (1) | Paul Gómez-Jauregui (1) | Ane Nieva-Zuluaga (1) | Natalia Sainz-Ramirez (1) | Maider Apodaka-Biguri (1) | Kendall Alfaro-Jiménez (1) | Lorena Mosteiro (3) | Gaizka Errazti (3) | Luis A Castaño (3) | Luis Bujanda (4,5,6) | Guadalupe Sabio (7) | Ruben Nogueiras (8,9) | Marco Arrese (10) | Javier Crespo (11) | Manuel Romero Gómez (12) | Rocío Aller (13) | Jesus Maria Bañales (4) | Beatriz Gómez-Santos (1,3) | Patricia Aspichueta (1,3,5)*

1- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain. | 2- Rubió Metabolomics, Derio, Spain | 3- Biobizkaia Health Research Institute, Barakaldo, Spain. | 4- Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute- Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain. | 5- Centre for Biomedical Network Research on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain. | 6- Ikerbasque, Basque Foundation for Science, Bilbao, Spain. | 7- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. | 8- CIBER Physiopathology of Obesity and Nutrition (CIBERObn), Madrid, Spain. | 9- Department of Physiology, CiMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain. | 10- The Global NASH Council, Washington, DC, USA; Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile. | 11- Marqués de Valdecilla University Hospital, Cantabria University, IDIVAL, Santander, Spain. | 12- Digestive Diseases and Ciberehd, Virgen del Rocio University Hospital, Institute of Biomedicine of Seville (CSIC/HUVR/US), University of Seville, Sevilla, Spain. | 13- Clinic University Hospital, University of Valladolid, Valladolid, Spain.

14.00 - 15.05



ALMUERZO



(Sin alcohol, ni refrescos)



VISITA POSTERS

15.05 - 16.45

SESIÓN 2. CONTRIBUCIÓN DEL MICROAMBIENTE TUMORAL EN LA RESPUESTA A INMUNOTERAPIA EN EL CÁNCER HEPÁTICO

Moderadores:

Marco Sanduzzi-Zamparelli (Barcelona)

Javier Vaquero (Salamanca)

15.05 - 15.25

Avances y retos de la inmunoterapia en cáncer hepático

Josep María Argemí (Pamplona)

15.25 - 15.45

Influencia del microambiente inmunitario tumoral en el cáncer
de hígado

María Jesús Perugorria (San Sebastián)

15.45 - 16.05

Papel de los fibroblastos en el desarrollo de los tumores hepáticos
y en la inmunosupresión

Silvia Affò (Barcelona)

16.05 - 16.25

Interacción entre células inmunitarias y endoteliales en la
progresión de la enfermedad hepática crónica

Rubén Francés (Alicante)

16.25 - 16.45

COMUNICACIÓN ORAL SELECCIONADA

Scavenger receptor MARCO acts as a modulator of the immunosuppressive tumor microenvironment and arises as a promising new therapeutic target for HCC

Maidier Huici-Izagirre (1) | Aloña Agirre-Lizaso (1) | Josu Urretabizkaia-Garmendia (1) | Beatriz Val (1,2) | Colm J O'Rourke (3) | Jesper B Andersen (3) | Elizabeth Hijona (1,2) | Adelaida La Casta (1) | Raul Jimenez-Aguero (1) | Luis Bujanda (1,2) | Pedro M Rodrigues (1,2,4) | Omar Sharif (5,6) | Jesus M Banales (1,2,4,7) | Maria J Perugorria (1,2,8)

1- Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute -Donostia University Hospital-, University of the Basque Country (UPV/EHU), San Sebastian, Spain

| 2- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), Spain | 3- Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark | 4- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 5- Institute for Vascular Biology, Centre for Physiology and Pharmacology, Medical University Vienna, Vienna, Austria | 6- Christian Doppler Laboratory for Immunometabolism and Systems Biology of Obesity-Related Diseases (InSpiReD), Vienna, Austria | 7- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain | 8- Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), San Sebastian, Spain.

16.45 - 17.15



CAFÉ



VISITA POSTERS

17.15 - 18.15

SESIÓN 3. MESA REDONDA: PARTICIPACIÓN CIUDADANA EN LA INVESTIGACIÓN

Moderadora:

María Varela (Oviedo)

- ◀ Investigador básico
Carmen Berasain (Pamplona)
- ◀ Investigador clínico
Antonio Guerrero (Madrid)
- ◀ Representante asociación pacientes ATUVIBI
Elisabeth Baucells (Barcelona)
- ◀ Representante AECC
Vanesa Abon (Madrid)
- ◀ Representante de FERO
Bárbara Fontanals (Barcelona)

18.15 - 19.50

SESIÓN 4. MECANISMOS DE DESARROLLO DE LA ENFERMEDAD CRÓNICA AL CÁNCER HEPÁTICO

Moderadoras:

Maite García Fernández-Barrena (Pamplona)

Mercedes Fernández (Barcelona)

18.15 - 18.35

Ciclo circadiano y control de la traducción en el cáncer hepático

Mercedes Fernández (Barcelona)

18.35 - 18.55

Papel del TGF beta en el desarrollo del colangiocarcinoma.

Javier Vaquero (Salamanca)

18.55 - 19.15

Impacto de la microbiota en el cáncer de hígado

Marco Sanduzzi-Zamparelli (Barcelona)

19.15 - 19.35

Papel del magnesio en el cáncer hepático.

María Luz Martínez Chantar (Bilbao)

19.35 - 19.50

COMUNICACIÓN ORAL SELECCIONADA

KLF15 Acts as a Tumor Suppressor in Cholangiocarcinoma by Inhibiting Cell Proliferation, Migration, and Mitochondrial Energetic Activity

Mireia Tena-Garitaonaindia (1) | Nuno A. Paiva (1) | Irune Lasca-Elosegi (1) | Paula Olaizola (1,2) | Ainhoa Lapitz (1,2) | Beatriz Val (1,2) | Colm J. O'Rourke (3) | Jesper B. Andersen (3) | Mikel Azkargorta (2,4) | Felix Elortza (2,4) | Luis Bujanda (1,2) | Maria J. Perugorria (1,2,5) | Pedro M. Rodrigues* (1,2,6) | Jesus M. Banales* (1,2,6,7)*

1- Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), Donostia-San Sebastian, Spain | 2- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), Spain | 3- Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark | 4- Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park, Derio | 5- Departments of Medicine and Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain | 6- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 7- Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

19.50 - 20.00

BIENVENIDA DEL PRESIDENTE

Rafael Bañares (Presidente de la AEEH, Madrid)

**08.45 - 10.20 SESIÓN 5. NUEVOS SISTEMAS DE DIAGNÓSTICO Y
TRATAMIENTO EN CÁNCER DE HÍGADO**

Moderadores:

María Varela (Oviedo)

Matías Ávila (Pamplona)

08.45 - 09.05 Nuevos métodos no invasivos para el manejo
del cáncer hepático
Pedro Rodrigues (San Sebastián)

09.05 - 09.25 Nanopartículas lipídicas: nuevas estrategias inmunoterapéuticas
en cáncer hepático
Alba Rodríguez García (Barcelona)

09.25 - 09.45 Terapia epigenética en los tumores hepáticos
Maite García Fernández-Barrena (Pamplona)

09.45 - 10.05 Terapias celulares personalizadas para el tratamiento
del cáncer hepático
Sandra Hervás (Pamplona)

10.05 - 10.20 COMUNICACIÓN ORAL SELECCIONADA

SLU7 silencing as a new anti-tumoral strategy

Carla Rojo (1) | Aaron Otero (1) | María Elizalde (1) | María Azkona
(1) | Álvaro Gutierrez-Uzquiza (2) | Laura Gueembe (3) | Diego
Alignani (4) | Amaia Lujambio (5) | Maite G Fernández-Barrena
(1,6,7) | Matías A Ávila (1,6,7) | María Arechederra (1,6,7) | Carmen
Berasain (1,6)

1- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. | 2- Department of Biochemistry and Molecular Biology, Pharmacy Faculty, Complutense University of Madrid, Madrid, Spain. | 3- Morphology Core Facility, CIMA, Pamplona, Spain. | 4- Flow Cytometry Core, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. | 5- Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA | 6- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), Madrid, Spain. | 7- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

10.20 - 11.00

SESIÓN 6. MESA REDONDA: DEL LABORATORIO A LA CLÍNICA: CLAVES PARA UNA INVESTIGACIÓN BIOMÉDICA CON IMPACTO SOCIAL

Moderadora:

María Arechederra (Pamplona)

- ◀ Biobanco como mediador de una investigación traslacional
María Antonia Fortuño (Pamplona)
- ◀ Cómo hacer una investigación colaborativa de tipo traslacional
Rocío Gallego (Sevilla)
- ◀ De la investigación a la empresa
María Luz Martínez Chantar (Bilbao)

11.00 - 11.30



CAFÉ



VISITA POSTERS

11.30 - 12.00 **SESIÓN 7. POSTER BLAST**

Moderadores:

Rocío Gallego (Sevilla)

Pedro Rodrigues (San Sebastián)

Poster N.º 2 - [Diagnóstico y tratamiento]

ZEB1 regulates BCL2 in cancer-associated fibroblasts to promote intrahepatic cholangiocarcinoma chemoresistance to gemcitabine and cisplatin

Ester Gonzalez-Sanchez (1,2,3) | Marie Vallette (4) | Aashreya Ravichandra (5) | Mirko Minini (4,6) | Allan Pavy (4) | Josep Amengual (7) | Carlos Andres Roldán-Hernández (1) | Corentin Louis (8) | Juan Jose Lozano (9) | Isabel Fabregat (3,7) | Nathalie Guedj (10) | Valérie Paradis (10) | Cedric Coulouarn (8) | Lynda Aoudjehane (11,12) | Laura Fouassier (4,6) | Javier Vaquero (1,3)

1- HepatoBiliary Tumours Lab, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca 37007, Spain | 2- Department of Physiology and Pharmacology, University of Salamanca, 37007, Salamanca, Spain | 3- National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain | 4- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France | 5- TUM School of Medicine and Health, Department of Clinical Medicine – Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich, Germany | 6- Université Paris Cité, CNRS, Inserm, NABI, F-75006 Paris, France | 7- TGF- β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain | 8- Inserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France | 9- Bioinformatic Platform, CIBERehd, Barcelona, Spain | 10- Service d'Anatomie Pathologique Hôpital Beaujon, F-92110 Clichy, France; INSERM, UMR 1149, Centre de Recherche sur l'Inflammation, F-75018, Paris, France | 11- ICAN BioCell-Human Liver Biology core, IHU - Foundation for innovation in Cardiometabolism and Nutrition (IHU-ICAN), F-75013 Paris, France | 12- Sorbonne Université, INSERM, UMRS 1166/IHU-ICAN, F-75013, Paris, France.

Poster N.º 16 [Enfermedad hepática crónica]

Outcomes of SGLT2 inhibitors in diabetes and cirrhosis after first episode of ascites: a retrospective cohort study

Daniel Riado Mínguez (1,2,3) | Flor María Fernández-Gordón Sánchez (2) | Sandra Agudo Fernández (2) | Cristina Cuadrado Tiemblo (2) | Carlos Castaño Milla (2)

1- Escuela Internacional de Doctorado, Universidad Rey Juan Carlos | 2- Hospital Universitario Rey Juan Carlos | 3- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM).

Poster N.º 23 [Mecanismos de la hepatocarcinogénesis]

Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma

Amaya Lopez-Pascual (1,2) | Emiliana Valbuena-Goiricelaya (1) | Jasmin Elurbide (1,3) | M. Ujué Latasa (1,3) | Elena Anaya (1) | Elena Adan-Villaescusa (1) | Borja Castelló-Urbe (1) | Iker Uriarte (1,3) | Maria Arechederra (1,2,3) | Fernando Corrales (4) | Leticia Colyn (5) | Patricia Inacio (5) | Robert Arnes-Benito (5) | Juan Bayo (6) | Meritxell Huch (5) | Carmen Berasain (1,3) | Maite G Fernández-Barrena (1,2,3) | Matías A. Ávila (1,2,3)

1- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. | 2- Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain. | 3- CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. | 4- Funcional Proteomics Laboratory, Centro Nacional de Biotecnología, CSIC, Madrid, Spain. | 5- Max Plank Institute of Molecular Cell Biology and Genetics, Dresden, Germany. | 6- Programa de Hepatología Experimental y Terapia Génica, Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, CONICET-Universidad Austral, Buenos Aires, Argentina.

Poster N.º 27 [Mecanismos de la hepatocarcinogénesis]

Chaperone-Mediated Autophagy is a Tumor-Suppressive Mechanism in hepatocellular carcinoma

Khushbu Patel (1,2) | Begona Zapateria (2,3) | Alex Ledet (2,4,4) | Antonio Díaz (2,5) | Simone Sidoli (2,6) | Ana Maria Cuervo (2,5) | Fernando Macian (1,2) | Esperanza Arias (2,3,7,8,9)

1- Department of Pathology | 2- Albert Einstein College of Medicine | 3- Department of Medicine (Hepatology) and Department of Pathology | 4- Department of Medicine (Hepatology) | 5- Department of Developmental and Molecular Biology | 6- Department of Biochemistry | 7- The Marion Bessin Liver Research Center | 8- Montefiore Einstein Comprehensive Cancer Center | 9- Einstein Nathan Shock Center of Excellence in the Basic Biology of Aging.

Poster N.º 29 [Microambiente tumoral]

High-Salt Diet Suppresses HCC Growth via Enhanced Anti-Tumor Immunity

Amalia Tzoumpa (1) | Joanna Pico (1) | Yin Huang (1) | Beatriz Lozano Ruiz (1) | Pedro Zapater (1) | Jose Manuel Gonzalez Navajas (1)

1- Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL).

Poster N.º 36 [Tecnologías y -ómicas]

The Mosaic of Malignancy: Exploring the Interactions Between Tumor Clones and Stroma in Intrahepatic Cholangiocarcinoma

Claudio Zampato (1) | Paula Cantallops-Vilà (1) | Gemma Garcia-Vicién (1) | Laura Sererols-Viñas (1) | Carmen I. Cárcamo-Giráldez (1) | Marsela Karemani (2) | Roser Pinyol (1) | Manel Esteller (3,4) | Robert F. Schwabe (5) | Anna Moles (1,6) | Josep M. Llovet (1,4,7) | Eduard Porta (3) | Silvia Affò (1)

1- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain | 2- Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain | 3- Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain | 4- Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain | 5- Columbia University, New York, New York, USA | 6- Institut d'Investigacions Biomèdiques de Barcelona (IIBB-CSIC), Barcelona, Spain | 7- Mount Sinai Liver Cancer Program, New York, United States.

Poster N.º 37 [Tecnologías y -ómicas]

Proteomic landscape of pediatric and adult liver cancer

Queralt Miñarro-Ribot (1) | Andrea Castaneda (1) | Maria Manuela Barranco (1,2) | Adel Aref (3) | Juanjo Lozano (4) | Rita Alaggio (5) | Maria Torner (6) | Laura Royo (1) | Álvaro del Río-Álvarez (1,2,7) | Lucia Lozano-White (1) | Paola Francalanci (5) | Rudolf Maibach (8) | Madhumita Dandapani (9) | Piotr Czauderna (10) | Margaret Childs (11) | Sophie Branchereau (12) | Bruce Morland (13) | Phil Robinson (3) | Rogger Reddel (3) | Carolina Armengol (1,2)

1- Childhood Liver Oncology Group, Germans Trias i Pujol Research Institute (IGTP), Program for Predictive and Personalized Medicine of Cancer (PMPPC), Badalona, Spain | 2- Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBEREHD), Institute of Health Carlos III, 28029 Madrid, Spain | 3- ProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia | 4- CIBEREHD, Bioinformatics platform, CIBEREHD, Institute of Health Carlos III, 28029 Madrid, Spain | 5- Pathology Unit, Department of Diagnostic and Laboratory Medicine, IRCCS Bambino Gesù Children's Hospital, Roma, Italy | 6- Hepatology Unit, Hospital Germans Trias i Pujol, Badalona, Spain | 7- School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain | 8- International Breast Cancer Study Group Coordinating Center, Berne, Switzerland | 9- Childrens Brain Tumour Research Centre, School of Medicine, University of Nottingham, UK. Nottingham University Hospitals NHS Trust, Nottingham, UK | 10- Medical University of Gdansk, Gdansk, Poland | 11- University of Nottingham, Nottingham, UK | 12- Department of Pediatric Surgery, Bicêtre Hospital, AP-HP, Paris-Saclay University, Le Kremlin-Bicêtre, France | 13- Department of Oncology, Birmingham Women's and Children's Hospital, Birmingham, UK.

12.00 - 12.20 ENTREGA DE PREMIOS

12.20 - 13.35 **SESIÓN 8. PROS Y CONTRAS DE LAS NUEVAS TECNOLOGÍAS
EN EL AVANCE DEL CONOCIMIENTO DEL CÁNCER HEPÁTICO**

Moderadoras:

Patricia Aspichueta (Bilbao)

Carmen Berasain (Pamplona)

12.20 - 12.40 Desarrollo de hígados bio-artificiales para el tratamiento de las enfermedades hepáticas crónicas

Sergio Rodríguez-Reynoso (Zaragoza)

12.40 - 13.00 Impacto de los exosomas en el entendimiento de la enfermedad hepática crónica

Félix Royo (Bilbao)

13.00 - 13.20 Patología digital e IA

María Jesús Fernández (Madrid)

13.20 - 13.35 COMUNICACIÓN ORAL SELECCIONADA

Caracterización del contexto inmune periférico mediante single-cell RNA seq en pacientes con carcinoma hepatocelular avanzado tratados con inmunoterapia

Mónica Higuera (1) | Agnès Soriano-Varela (1,2) | Maria Torrens (1,2) | María Montesinos (1) | Xavier Merino (3) | Beatriz Mínguez (1,2,4,5)

1- Grupo de investigación en cáncer de hígado, Enfermedades Hepáticas, Institut de Recerca Vall d'Hebron (VHIR), Campus Hospital Universitario Vall d'Hebron, Barcelona | 2- Unidad de Hepatología, Hospital Universitario Vall d'Hebron, Campus universitario Vall d'Hebron, Barcelona | 3- Unidad de Radiología, Hospital Universitario Vall d'hebron, Campus universitario Vall d'Hebron, Barcelona | 4- Departamento de Medicina, Universitat Autònoma de Barcelona (UAB), Bellaterra | 5- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid.

13.45 - 14.30 **KEYNOTE LECTURE (II)**

Moderadora:

Silvia Affò (Barcelona)

Integración de -ómicas para la clasificación molecular de los tumores hepáticos y predicción de la respuesta a tratamiento

Josep María Llovet (Barcelona)

14.30 **CLAUSURA**

POSTER SESSION

ÁREA TEMÁTICA

PÓSTER

DIAGNÓSTICO Y TRATAMIENTO

1 - 11

ENFERMEDAD HEPÁTICA CRÓNICA

12 - 22

MECANISMOS DE LA HEPATOCARCINOGENÉISIS

23 - 28

MICROAMBIENTE TUMORAL

29 - 35

TECNOLOGÍAS Y -ÓMICAS

36 - 40

DIAGNÓSTICO Y TRATAMIENTO

PÓSTER N.º 1

Selective class I histone deacetylases inhibitors derived from ursodeoxycholic acid as a novel treatment strategy for bile duct cancer

Noelia Pastor-Toyos (1) | Francisco Javier Caballero-Camino (1,2) | Irene Olaizola (1) | Iván Rivilla (3,4) | Amanda R. Guimaraes (3) | Pedro M. Rodrigues (1,2,4) | Luis Bujanda (1,2,5) | Fernando P. Cossío (3) | Jesus M. Banales (1,2,4,6)

1- Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain | 2- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), Madrid, Spain | 3- Department of Organic Chemistry I, Center of Innovation in Advanced Chemistry (ORFEO-CINQA), Faculty of Chemistry, University of the Basque Country (UPV/EHU) & Donostia International Physics Center (DIPC), San Sebastian, Spain | 4- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 5- Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), San Sebastian, Spain | 6- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

PÓSTER N.º 2 ✨ POSTER BLAST ✨

ZEB1 regulates BCL2 in cancer-associated fibroblasts to promote intrahepatic cholangiocarcinoma chemoresistance to gemcitabine and cisplatin

Ester Gonzalez-Sanchez (1,2,3) | Marie Vallette (4) | Aashreya Ravichandra (5) | Mirko Minini (4,6) | Allan Pavy (4) | Josep Amengual (7) | Carlos Andres Roldán-Hernández (1) | Corentin Louis (8) | Juan Jose Lozano (9) | Isabel Fabregat (3,7) | Nathalie Guedj (10) | Valérie Paradis (10) | Cedric Coulouarn (8) | Lynda Aoudjehane (11,12) | Laura Fouassier (4,6) | Javier Vaquero (1,3)

1- HepatoBiliary Tumours Lab, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca 37007, Spain | 2- Department of Physiology and Pharmacology, University of Salamanca, 37007, Salamanca, Spain | 3- National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain | 4- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France | 5- TUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich, Germany | 6- Université Paris Cité, CNRS, Inserm, NABI, F-75006 Paris, France | 7- TGF- β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain | 8- Inserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) UMR_S 1242,

DIAGNÓSTICO Y TRATAMIENTO

Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France | 9- Bioinformatic Platform, CIBERehd, Barcelona, Spain | 10- Service d'Anatomie Pathologique Hôpital Beaujon, F-92110 Clichy, France; INSERM, UMR 1149, Centre de Recherche sur l'Inflammation, F-75018, Paris, France | 11- ICAN BioCell-Human Liver Biology core, IHU - Foundation for innovation in Cardiometabolism and Nutrition (IHU-ICAN), F-75013 Paris, France | 12- Sorbonne Université, INSERM, UMRS 1166/IHU-ICAN, F-75013, Paris, France.

PÓSTER N.º 3

Los TKIs inhiben las bombas MRP exportadoras de fármacos y potencian la respuesta de las células de carcinoma hepatocelular a la quimioterapia

Maria Reviejo (1,2,3) | Ana Peleteiro-Vigil (4) | Anabel Sanchez-Martin (4) | Oscar Briz (2,3,4) | Marta R. Romero (3,4,5) | Rocio I.R. Macias (2,3,4) | Maria J. Monte (2,3,4) | Helen S Hammer (6) | Oliver Pötz (7,8) | Mar Abad (5,9) | Jose J.G. Marin (2,3,4) | Elisa Herraez (2,3,4)

1- Grupo de Hepatología experimental y vectorización de fármacos (HEVEPHARM), Universidad de Salamanca, Salamanca, España | 2- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España. | 3- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd, Instituto de Salud Carlos III). Madrid, España. | 4- Grupo de Hepatología experimental y vectorización de fármacos (HEVEPHARM), Universidad de Salamanca, Salamanca, España. | 5- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España | 6- Signatope GmbH, Reutlingen, Alemania. | 7- Signatope GmbH, Reutlingen, Alemania | 8- Instituto de Ciencias Naturales y Médicas de la Universidad de Tubinga (NMI), Reutlingen, Alemania. | 9- Departamento de Anatomía Patológica, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, España.

PÓSTER N.º 4

Evaluación de la Alfa-fetoproteína como Indicador Pronóstico en el Tratamiento del Carcinoma Hepatocelular con Atezolizumab-Bevacizumab

Lide Martinez Insausti (1) | Raisa Quiñones-Castro (2) | Clara Barneo-Caragol (1,3) | Andrés Castaño García (4) | Paula Fernández-Álvarez (4) | Diana Boada Ortega (2) | Ana M Piedra Cerezal (4) | Manuel Rodríguez (3,4,5) | Valentina Chiminazzo (3) | María Varela (3,4,5,6)

1- Servicio de Bioquímica Clínica. HUCA | 2- Servicio de Digestivo. Hospital Universitario de León | 3- ISPA.FINBA | 4- Servicio de Digestivo. HUCA | 5- Universidad de Oviedo | 6- IUOPA.

DIAGNÓSTICO Y TRATAMIENTO

PÓSTER N.º 5

Validation of biomarkers in Hepatoblastoma: An international effort to support their integration in the clinical setting

Andrea Castaneda (1) | Maria Manuela Barranco Piazza (1,2) | Lucia Lozano White (1) | Rita Alaggio (3) | Madhumita Dandapani (4) | Sophie Branchereau (5) | Piotr Czauderna (6) | Eiso Hiyama (7) | Dolores López-Terrada (8) | Pavel Sumazin (9) | Carolina Armengol (1,2)

1- Childhood Liver Oncology Group, Germans Trias i Pujol Research Institute (IGTP), Program for Predictive and Personalized Medicine of Cancer (PMPPC), Badalona, Spain | 2- Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBER), Institute of Health Carlos III, 28029 Madrid, Spain | 3- Pathology Unit, Department of Diagnostic and Laboratory Medicine, IRCCS Bambino Gesù Children's Hospital, Roma, Italy | 4- Childrens Brain Tumour Research Centre, School of Medicine, University of Nottingham, UK. Nottingham University Hospitals NHS Trust, Nottingham, UK | 5- Department of Pediatric Surgery, Bicêtre Hospital, AP-HP, Paris-Saclay University, Le Kremlin-Bicêtre, France. | 6- Medical University of Gdansk, Gdansk, Poland | 7- Department of Biomedical Science, Natural Science Center for Basic Research and Development (N-BARD), Hiroshima University, Hiroshima, Japan. | 8- Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital and Cancer Center, Houston, TX, USA; Department of Pathology & Immunology, Baylor College of Medicine, Texas Children's Hospital and Cancer Center, Houston, TX, USA | 9- Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital and Cancer Center, Houston, TX, USA.

PÓSTER N.º 6

TGF- β pathway alterations define sensitivity to TGF- β receptor blockade in extrahepatic biliary tract cancer

Ana Martin-Ramírez (1) | Itziar Rodríguez-Rivas (1) | Carlos Andrés Roldán-Hernández (1) | Josep Amengual (2,3) | Isabel Fabregat (2,3) | Ester Gonzalez-Sanchez (1,3,4) | Javier Vaquero (1,3)

1- HepatoBiliary Tumours Lab, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca 37007, Spain | 2- TGF- β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain | 3- CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III, Madrid, Spain | 4- Department of Physiology and Pharmacology, University of Salamanca, 37007, Salamanca, Spain.

DIAGNÓSTICO Y TRATAMIENTO

PÓSTER N.º 7

Evaluación de un índice de daño histológico adaptado a un modelo animal de MASLD

Paula Orejas (1) | Álvaro Hidalgo (1) | Yanara Senra (1) | Silvia Sacristán (1) | Óscar Pastor (1,2)

1- Servicio de Bioquímica Clínica. Hospital Universitario Ramón y Cajal-IRYCIS, Madrid | 2- Dpto. Fisiología. Universidad de Alcalá, Alcalá de Henares.

PÓSTER N.º 8

Desarrollo de nuevas sublíneas celulares de colangiocarcinoma con resistencia a cisplatino o 5-fluorouracilo

Kevin Delgado-Calvo (1,2) | Óscar Briz (1,2) | Candela Cives-Losada (3,4) | Rebeca P. Marijuan (1) | Elisa Herráez (1,2) | Maitane Asensio (1,2) | María A. Serrano (1,2) | Laura Pérez-Silva (1,2) | Nazaret Hortelano-Hernandez (1,2) | Laura Álvarez-Fernández (1) | José J.G. Marín (1,2) | Rocío I.R. Macías (1,2) | Elisa Lozano (1,2)

1- Hepatología Experimental y Vectorización de Fármacos, Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Salamanca. | 2- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto Nacional de Salud Carlos III, Madrid. | 3- Laboratorio de Inmunopatología Hepatobiliar, Istituto Clinico Humanitas Research Hospital, Rozzano, Milán, Italia. | 4- Departamento de Ciencias de la Salud, Università del Piemonte Orientale, Novara, Italia.

PÓSTER N.º 9

Predicción de eventos cardiovasculares mayores después del trasplante hepático mediante supervised machine learning model

Santiago Rodríguez Villafuerte (1,2)

1- Hospital Vozandes, Quito - Ecuador | 2- Dirección General de Posgrados en Salud. Universidad de las Américas. Quito - Ecuador.

PÓSTER N.º 10

Performance de scores pronósticos que incluyen datos del explante para estimar la recurrencia del carcinoma hepatocelular después del trasplante hepático: Una revisión sistemática y metanálisis

Santiago Rodríguez Villafuerte (1,2) | Iago Christofoli de Barros (3) | Matheus Vanzin Fernandes (3) | Ajaccio Brandão (3)

1- Departamento Hepatología. Hospital Vozandes. Quito - Ecuador | 2- Dirección de Posgrados en Salud. Universidad de las Américas. Quito - Ecuador | 3- Graduate Program in Medicine: Hepatology, School of Medicine, Univ. Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Brasil.

DIAGNÓSTICO Y TRATAMIENTO

PÓSTER N.º 11

Cholangiocarcinoma in individuals with chronic liver disease is diagnosed earlier, leading to better prognosis

Jone Narbaiza (1) | Laura Izquierdo-Sanchez (1,2) | Angela Lamarca (3) | Adelaida La Casta (1) | Heinz-Josef Klumpen (4) | Arun Valsan (5) | Stephanie Roessler (6,7) | Chiara Braconi (8,9) | Leonardo G. da Fonseca (10,11) | Cristina Dopazo (12,13) | Trine Folseraas (14,15,16,17) | Bas Groot Koerkamp (18) | Domingo Balderramo (19) | Mariano Ponz-Sarvisé (20) | Javier Díaz Ferrer (21) | Krzysztof Zieniewicz (22) | Zeno Sparchez (23) | Kirsten Utpatel (24) | Markus Peck-Radosavljevic (25) | Alejandro Forner (2,26) | Ylenia Pérez Castaño (1) | Luis Bujanda (1,2) | Jesus M. Banales (1,2,27,28) | on behalf of the International Cholangiocarcinoma Registry.

1- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain | 2- National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, "Instituto de Salud Carlos III" (ISCIII), Madrid, Spain | 3- Department of Medical Oncology, The Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester, UK | 4- Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, the Netherlands | 5- Department of Hepatology and Gastroenterology, Amrita Institute of Medical Sciences and Research (AIMS), Kochi, India | 6- Institute of Pathology, Heidelberg University, ImNeuenheimer Feld 224, Heidelberg, Germany | 7- Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany | 8- Institute of Cancer Sciences, University of Glasgow, UK | 9- The Royal Marsden NHS Trust, London & Surrey, UK | 10- Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil | 11- São Paulo Clínicas Liver Cancer Group, Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil | 12- Department of Surgery, School of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain | 13- Department of Hepatic and Biliary Surgery and Transplants, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain | 14- Norwegian PSC Research Center, Department of Transplantation Medicine, Oslo University, Hospital Rikshospitalet, Oslo, Norway | 15- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway | 16- Research Institute of Internal Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway | 17- Section of Gastroenterology, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway | 18- Department of Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands | 19- Gastroenterology Department, Hospital Privado Universitario de Córdoba, Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina

DIAGNÓSTICO Y TRATAMIENTO

| 20- Clinica Universidad de Navarra and Program in Solid Tumors (CIMA), Universidad de Navarra, IDISNA, Pamplona, Spain | 21- Departamento del Aparato Digestivo, Hospital Nacional Edgardo Rebagliati Martins-Essalud, Facultad de Medicina, Universidad De San Martin De Porres, Lima, Peru | 22- Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Poland | 23- 3rd Medical Department, Institute for Gastroenterology and Hepatology, University of Medicine and Pharmacy, Cluj Napoca, Romania | 24- Institute of Pathology, University of Regensburg, Regensburg, Germany | 25- Internal Medicine and Gastroenterology (IMuG) and Emergency Medicine (ZAE), Klinikum Klagenfurt Am Wörthersee, Klagenfurt, Austria | 26- Liver Unit, Barcelona Clinic Liver Cancer (BCLC) group, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Spain | 27- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain | 28- Ikerbasque, Basque Foundation for Science, Bilbao, Spain.

ENFERMEDAD HEPÁTICA CRÓNICA

PÓSTER N.º 12

El bloqueo de la vía PAF/PAF-R con un ligando antagonista reduce el daño hepático en un modelo de enfermedad hepática crónica

Enrique Ángel-Gomis (1,2,3) | Oriol Juanola (1,2,3) | Isabel Gómez-Hurtado (1,2,4) | Paula Boix Navarro (1,2) | Hong Liang (1,3) | Benedikt Simbrunner (5) | Esther Caparrós (1,2,3) | Rubén Francés (1,2,3,4)

1- Grupo de Inmunobiología Hepática e Intestinal. Departamento de Medicina Clínica. Universidad Miguel Hernández, San Juan, Alicante. España. | 2- Instituto de Investigación Sanitaria ISABIAL. Hospital Universitario Dr. Balmis, Alicante. España. | 3- Instituto de Investigación IDiBE. Universidad Miguel Hernández de Elche, Elche. España. | 4- CIBERehd, Instituto de Salud Carlos III. Madrid. España. | 5- División de Gastroenterología y Hepatología. Departamento de Medicina III, Universidad Médica de Viena.

PÓSTER N.º 13

Mitochondrial dynamics and auto(mito)phagy are altered in experimental models of Primary Biliary Cholangitis, contributing to disease pathogenesis

Irene Lasa-Elosegi (1) | Laura Izquierdo-Sanchez (1,2) | Paula Olaizola (1,2) | Ainhoa Lapitz (1,2) | Mireia Tena-Garitaonaindia (1) | Santiago Iturbe-Rey (1) | Beatriz Val (1) | Maite García Fernandez-Barrena (2,3,4) | Luis Bujanda (1,2,5) | M. Jesus Perugorria (1,2,5) | Pedro M. Rodrigues (1,2,6) | Jesus M. Banales (1,2,6,7)

1- Department of Liver and Gastrointestinal Diseases, Biogipuzka Health Research Institute – Donostia University Hospital –, University of the Basque Country (UPV/EHU), San Sebastian, Spain | 2- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), Spain | 3- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, 3008, Pamplona, Spain | 4- IdiSNA, Navarra Institute for Health Research, 31008, Pamplona, Spain | 5- Departments of Medicine, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, San Sebastian, Spain | 6- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 7- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

ENFERMEDAD HEPÁTICA CRÓNICA

PÓSTER N.º 14

Effect of Bile Acids on Hepatocyte Plasticity in Chronic Liver Disease

Carlos Mateos-Sánchez (1) | Beatriz Aguilar-Bravo (1) | Raquel Ferrer-Lorente (1) | Laura Zanatto (1) | Zhengqing Xu (1) | Maria Mercado-Gómez (1) | Laura Garcia-Tercero (1) | Marc Miravet-Martí (1) | Alicia Martínez-Álvarez (1) | Laia Aguilar-Corominas (1) | Juan José Lozano (2) | Mar Coll (1,2,3) | Ramón Bataller (1,2,3,4) | Pau Sancho-Bru (1,2,3)

1- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. | 2- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. | 3- Universitat de Barcelona (UB), Barcelona, Spain. | 4- Liver Unit, Hospital Clinic, Barcelona, Spain.

PÓSTER N.º 15

Combined effect of Atorvastatin and Ambrisentan on the hemodynamic alterations and liver fibrosis in a translational rat model of MASLD with advanced fibrosis

M Serra Cusidó (1,2) | Imma Raurell (1,3) | María Martínez-Gómez (1,2,4) | Núria Juan-Benítez (1,2) | Sophia C. Parks (1) | Juan M. Pericàs (1,2,3,4) | María Martell (1,2,3) | Joan Genescà (1,2,3,4)

1- Liver Disease Group, Vall d'Hebron Research Institute (VHIR) | 2- Universitat Autònoma de Barcelona | 3- Liver Unit, Area of Digestive Diseases, Hospital Universitari Vall d'Hebron | 4- Spanish Network of Biomedical Research Centers, Liver and Digestive Diseases (CIBERehd).

PÓSTER N.º 16 ✨ POSTER BLAST ✨

Outcomes of SGLT2 inhibitors in diabetes and cirrhosis after first episode of ascites: a retrospective cohort study

Daniel Riado Mínguez (1,2,3) | Flor María Fernández-Gordón Sánchez (2) | Sandra Agudo Fernández (2) | Cristina Cuadrado Tiemblo (2) | Carlos Castaño Milla (2)

1- Escuela Internacional de Doctorado, Universidad Rey Juan Carlos | 2- Hospital Universitario Rey Juan Carlos | 3- Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM).

ENFERMEDAD HEPÁTICA CRÓNICA

PÓSTER N.º 17

Dysregulation of the E2F2-PCSK9 axis in MASLD increases risk of cardiovascular disease and progression to hepatocellular carcinoma

Maidar Apodaka-Biguri (1) | Beatriz Gómez-Santos (1) | Xabier Buqué (1,2) | Ane Nieva-Zuluaga (1) | Mikel Ruiz de Gauna (1) | Idoia Fernandez-Puertas (1) | Paul Gómez-Jauregui (1) | Natalia Sainz-Ramirez (1) | Kendall Alfaro-Jimenez (1) | Estibaliz Castellero (1) | Ane Ortiz-Palma (1) | Unai Garzon Basterra (1) | Roxana Adriana Stoica (1) | Amaia Lujambio (3) | Xiaoke Ge (4) | Sander Kooijman (4) | Patrick Rensen (4) | Ana M. Zubiaga (5) | Patricia Aspichueta (1,2,6)

1- Department of Physiology University of the Basque Country UPV/EHU, Faculty of Medicine and Nursing, Leioa, Spain | 2- Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain | 3- Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA | 4- Dept. of Medicine, Div. of Endocrinology, Leiden University Medical Center, Leiden, Netherlands. | 5- Department of Genetic, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of Basque Country UPV/EHU, Leioa, Spain | 6- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), Madrid, Spain.

PÓSTER N.º 18

Unveiling the uNKTknown: the role of CD1d in MASLD is dependent on sex and diet

Carlos Cuño Gómiz (1,2,3) | Anna Tutusaus López (1,3,4,5) | Flavia Savino (1,2,3) | Diba Zare (1,2,3) | Patricia Rider García (1,2,3,4,5) | Albert Morales Muñoz (1,3,4,5) | Montserrat Marí García (1,3,4,5)

1- Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC), Barcelona (Spain) | 2- Departament de Biomedicina, Universitat de Barcelona (UB), Barcelona (Spain) | 3- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona (Spain) | 4- Barcelona Clinic Liver Cancer Center (BCLC), Hospital Clínic de Barcelona, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona (Spain) | 5- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD).

PÓSTER N.º 19

Pitpnm3, a new target of the HGF/Met pathway in hepatic progenitor cells

María Figueroa Fuentes (1,2) | Carlos González Corralejo (1,2) | Juan García Sáez (1,2) | Cesáreo Roncero (1,2) | Álvaro Gutiérrez Uzquiza (1,2) | Paloma Bragado Domingo (1,2) | Eva Fernández Calderón (1) | Sonia Castillo (3) | Blanca Herrera (1,2,4) | Aránzazu Sánchez (1,2,4)

ENFERMEDAD HEPÁTICA CRÓNICA

1- Dept. of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain. | 2- Health Research Institute of the "Hospital Clínico San Carlos" (IdISSC), Madrid, Spain. | 3- Dept. of Biochemistry and Molecular Biology, Faculty of Chemistry, Complutense University of Madrid (UCM), Spain. | 4- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD-ISCIII), Madrid, Spain.

PÓSTER N.º 20

Impact of c-Met enhanced levels on the properties and tumorigenic potential of adult hepatic progenitor cells

Juan García-Sáez (1) | María Figueroa-Fuentes (1) | Cesáreo Roncero (1) | Mónica Musteanu (1,2) | Laura McMahon (1) | Rubén Tacero (1) | Eva Fernández Calderón (1) | Beatriz Pacheco (1,3) | Paloma Bragado (1,3) | Julián Sanz (4,5) | Cristina Gato (4) | Silvia Calero Pérez (6,7) | Ángela Martínez Valverde (6,7) | María García Bravo (8,9) | Flavio Maina (10) | Almudena Porras (1,3) | Isabel Fabregat (11,12) | Blanca Herrera (1,3,12) | Aránzazu Sánchez (1,3,12)

1- Dept. Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Madrid, Madrid, España | 2- Biomedical Research Networking Center in Cancer (CIBERONC-ISCIII), Madrid, Madrid, España | 3- Health Research Institute of the "Hospital Clínico San Carlos" (IdISSC), Madrid, Madrid, España | 4- Anatomical Pathology Service of the "Clínica Universidad de Navarra", Madrid, Madrid, España | 5- Dept. Psychiatry, Legal Medicine and Anatomical Pathology, Faculty of Medicine, UCM, Madrid, Madrid, España | 6- Sols Morreale' Biomedical Research Institute, Spanish National Research Council and Autonomous University of Madrid (IIBM, CSIC-UAM), Madrid, Madrid, España | 7- Biomedical Research Networking Center in Diabetes and Associated Metabolic Disorders of the Carlos III Health Institute (CIBERDEM-ISCIII), Madrid, Madrid, España | 8- Cell Technology Division, Biomedical Innovation Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Madrid, España | 9- Biomedical Research Networking Center in Rare Diseases of the Carlos III Health Institute (CIBERER-ISCIII), Madrid, Madrid, España | 10- Aix Marseille Univ, Inserm, CNRS, "Centre de Recherche en Cancérologie de Marseille" (CRCM), Institut Paoli-Calmettes, Turing Center for Living Systems, Marseille, France, Metropolitan | 11- TGF-beta and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Barcelona, España | 12- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD-ISCIII), Madrid, Madrid, España.

ENFERMEDAD HEPÁTICA CRÓNICA

PÓSTER N.º 21

Impact of thermoneutral housing in acute-on chronic alcohol related liver disease

Monica Barrios (1,2,3,4) | Laura Fàbrega (1,2,3,4) | Susana Nuñez (1,2,5) | Carmen García-Ruiz (2,3,6,7) | José Carlos Fernández-Checa (1,2,7,8)

1- Department of Molecular and Cellular Biomedicine, Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona, Spain | 2- Liver Unit, Hospital Clinic i Provincial de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain | 3- CIBERehd, Instituto de Salud Carlos III, Madrid, Spain | 4- Faculty of Medicine-University of Barcelona, Barcelona, Spain | 5- Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain | 6- Department of Molecular and Cellular Biomedicine, Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona, Spain | 7- Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California | 8- CIBERehd) Instituto de Salud Carlos III, Madrid, Spain.

PÓSTER N.º 22

Evaluating semaglutide and lifestyle interventions in a novel dietary rat model of metabolic and alcohol-related liver disease with advanced fibrosis

María Martínez-Gómez (1,2,3) | Imma Raurell (1,4) | M Serra Cusidó (1,2) | Sophia C. Parks (1) | Joan Genescà (1,2,3,4) | María Martell (1,2,4) | Meritxell Ventura-Cots (1,2,4) | Juan M. Pericàs (1,2,3,4)

1- Liver Disease Group, Vall d'Hebron Research Institute (VHIR) | 2- Universitat Autònoma de Barcelona | 3- Spanish Network of Biomedical Research Centers, Liver and Digestive Diseases (CIBERehd) | 4- Liver Unit, Area of Digestive Diseases, Hospital Universitari Vall d'Hebron.

MECANISMOS DE LA HEPATOCARCINOGENÉISIS

PÓSTER N.º 23 ★ POSTER BLAST ★

Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma

Amaya Lopez-Pascual (1,2) | Emiliana Valbuena-Goiricelaya (1) | Jasmin Elurbide (1,3) | M. Ujué Latasa (1,3) | Elena Anaya (1) | Elena Adan-Villaescusa (1) | Borja Castelló-Urbe (1) | Iker Uriarte (1,3) | Maria Arechederra (1,2,3) | Fernando Corrales (4) | Leticia Colyn (5) | Patricia Inacio (5) | Robert Arnes-Benito (5) | Juan Bayo (6) | Meritxell Huch (5) | Carmen Berasain (1,3) | Maite G Fernández-Barrena (1,2,3) | Matías A. Ávila (1,2,3)

1- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. | 2- Instituto de Investigaciones Sanitarias de Navarra IdISNA, Pamplona, Spain. | 3- CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. | 4- Functional Proteomics Laboratory, Centro Nacional de Biotecnología, CSIC, Madrid, Spain. | 5- Max Plank Institute of Molecular Cell Biology and Genetics, Dresden, Germany. | 6- Programa de Hepatología Experimental y Terapia Génica, Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, CONICET-Universidad Austral, Buenos Aires, Argentina.

PÓSTER N.º 24

Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma

Pedro M. Rodrigues (1,2,3) | Ana Landa-Magdalena (1) | Oihane Erice (1) | Nuno A. Paiva (1) | Maite G. Fernandez-Barrena (2,4) | Paula Olaizola (1,2) | Ainhoa Lapitz (1,2) | Francisco J. Caballero-Camino (1,2) | Noelia Pastor-Toyos (1) | Beatriz Val (1,2) | Irene Olaizola (1) | Santiago Iturbe-Rey (1) | Colm J. O'Rourke (5) | Jesper B. Andersen JB (5) | Diego F. Calvisi (6) | Mikel Azkargorta (2,7) | Felix Elortza (2,7) | Ibai Goicoechea (8) | Charles H. Lawrie (3,8,9) | Luis Bujanda (1,2) | Maria J. Perugorria (1,2,10) | Jesus M. Banales (1,2,3,11)

1- Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute – Donostia University Hospital –, University of the Basque Country (UPV/EHU), San Sebastian, Spain | 2- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), Spain | 3- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain; 4-Division of Hepatology, CIMA-University of Navarra, Pamplona, Spain | 4- Division of Hepatology, CIMA-University of Navarra, Pamplona, Spain | 5- Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark | 6- Institute of Pathology, University of Regensburg, Regensburg, Germany | 7- Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park,

MECANISMOS DE LA HEPATOCARCINOGENÉISIS

Derio, Spain | 8- Molecular Oncology group, Biodonostia Research Institute, San Sebastian, Spain | 9- Radcliffe Department of Medicine, University of Oxford, UK | 10- Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain | 11- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

PÓSTER N.º 25

The arginine methyltransferase CARM1 as a novel potential therapeutic target in Hepatocellular Carcinoma

Elena Adan-Villaescusa (1) | Jasmin Elurbide (1,2) | Sara Luengo (1) | Amaya López-Pascual (1,3) | Ainara Irigaray-Miramón (1) | Borja Castello-Urbe (1) | Iker Uriarte (1,2) | María Ujue Latasa (1) | Emiliana Valbuena-Goicicelaya (1) | Roberto C. Barbero (1,2) | Miriam Belzunce (1) | Bruno Sangro (2,3,4) | María Arechederra (1,2,3) | Carmen Berasain (1,2) | Mark T Bedford (5) | Veronica Gibaja (6) | Matias A Avila (1,2,3) | Maite G Fernandez-Barrena (1,2,3)

1- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. | 2- CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. | 3- Instituto de Investigaciones Sanitarias de Navarra IdISNA, Pamplona, Spain. | 4- Hepatology Unit, CCUN, Navarra University Clinic, Pamplona, Spain. | 5- Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. | 6- Ipsen Biopharmaceuticals, Cambridge, Massachusetts, USA.

PÓSTER N.º 26

Characterization of the role of SLU7 in protein translation

Aaron Otero Ambulay (1) | Carla Rojo (1) | Maite Gueime (1) | María Elizalde (1) | María Azkona (1) | Sergio Ciordia (2) | Fernando Corrales (2) | Maite G Fernández-Barrena (1,3,4) | Matías A Ávila (1,3,4) | María Arechederra (1,3,4) | Carmen Berasain (1,4)

1- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain | 2- Proteomics Facility. National Center for Biotechnology. Universidad Autónoma de Madrid. Cantoblanco. 28049 Madrid, Spain | 3- IdISNA, Navarra Institute for Health Research, Pamplona, 31008, Spain. | 4- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), Madrid, 28029, Spain.

MECANISMOS DE LA HEPATOCARCINOGENÉISIS

PÓSTER N.º 27 ★ POSTER BLAST ★

Chaperone-Mediated Autophagy is a Tumor-Suppressive Mechanism in hepatocellular carcinoma

Khushbu Patel (1,2) | Begona Zapateria (2,3) | Alex Ledet (2,4,4) | Antonio Diaz (2,5) | Simone Sidoli (2,6) | Ana Maria Cuervo (2,5) | Fernando Macian (1,2) | Esperanza Arias (2,3,7,8,9)

1- Department of Pathology | 2- Albert Einstein College of Medicine | 3- Department of Medicine (Hepatology) and Department of Pathology | 4- Department of Medicine (Hepatology) | 5- Department of Developmental and Molecular Biology | 6- Department of Biochemistry | 7- The Marion Bessin Liver Research Center | 8- Montefiore Einstein Comprehensive Cancer Center | 9- Einstein Nathan Shock Center of Excellence in the Basic Biology of Aging.

PÓSTER N.º 28

Identification of molecular targets mediating TGF- β protumorigenic effects in intrahepatic cholangiocarcinoma

Carlos Andrés Roldán-Hernández (1) | Ana Martín-Ramírez (1) | Josep Amengual (2,3) | Beatriz Martín-Mur (4,5) | Isabel Fabregat (2,3) | Ester Gonzalez-Sanchez (1,3,6) | Javier Vaquero (1,3)

1- HepatoBiliary Tumours Lab, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca 37007, Spain | 2- TGF- β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain | 3- National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain | 4- Centro Nacional de Análisis Genómico (CNAG), C/Baldiri Reixac 4, 08028 Barcelona, Spain | 5- University of Barcelona (UB), 08034 Barcelona, Spain | 6- Department of Physiology and Pharmacology, University of Salamanca, 37007, Salamanca, Spain.

MICROAMBIENTE TUMORAL

PÓSTER N.º 29 ★ POSTER BLAST ★

High-Salt Diet Suppresses HCC Growth via Enhanced Anti-Tumor Immunity

Amalia Tzoumpa (1) | Joanna Pico (1) | Yin Huang (1) | Beatriz Lozano Ruiz (1) | Pedro Zapater (1) | Jose Manuel Gonzalez Navajas (1)

1- Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL).

PÓSTER N.º 30

El análisis de RNAseq de célula única revela paralelismos moleculares entre células tumorales circulantes y los núcleos tumorales en carcinoma hepatocelular

Mónica Higuera (1) | Agnès Soriano-Varela (1,2) | Maria Torrens (1,2) | María Montesinos (1) | Beatriz Mínguez (1,2,3,4)

1- Grupo de investigación en cáncer de hígado, Enfermedades Hepáticas, Institut de Recerca Vall d'Hebron (VHIR), Campus Hospital Universitari Vall d'Hebron, Barcelona | 2- Unidad de Hepatología, Hospital Universitario Vall d'Hebron, Campus universitario Vall d'Hebron, Barcelona | 3- Departamento de Medicina, Universitat Autònoma de Barcelona, Bellaterra | 4- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid.

PÓSTER N.º 31

GATA4 Reprograms activated Hepatic Stellate Cells to Inhibit Hepatocellular Carcinoma

Rubén Tacero (1) | Irene Díaz (1,2) | Noelia Arroyo (1) | Ignacio G López-Cepero (1) | Laura Zarzuela (1) | María Ángeles Cáliz- Molina (1) | Raúl V. Durán (1) | Alejandro Martín Montalvo (1,3) | David A Cano (4) | Anabel Rojas (1,2)

1- 1Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Universidad Pablo de Olavide, Universidad de Sevilla, Consejo Superior de Investigaciones Científicas (CSIC), Seville, Spain. | 2- 2Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain | 3- 2Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain. | 4- Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.

PÓSTER N.º 32

Induction, distribution and clinical relevance of immunosuppressive cancer-associated fibroblasts in intrahepatic cholangiocarcinoma

Gemma García-Vicién (1) | Paula Cantallops-Vilà (1) | Laura Sererols-Viñas* (1) | Raquel Martínez-García de la Torre (1) | Qing Xu (1) | Aashreya Ravichandra (2) | Carmen I. Cárcamo-Giráldez (1) | Claudio Zampato (1) | Joana Ferrer (3,4,5,6) | Maria Reig (3,4,5,7) | Alejandro Forner (3,4,5,7) | Alba Díaz (3,4,5,8) | Pau Sancho-Bru (1,4,5) | Silvia Affò (1)*

1- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain | 2- Medical Clinic and Polyclinic II, Klinikum Rechts Der Isar, Technical University Munich, Munich, Germany | 3- Barcelona Clinic Liver Cancer (BCLC) Group, IDIBAPS, Barcelona, Spain | 4- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain | 5- Facultad de Medicina, Universitat de Barcelona, Barcelona, Spain | 6- Hepatobiliopancreatic Surgery and Liver and Pancreatic Transplantation Unit, Department of Surgery, Liver Oncology Unit, Instituto Clínic de Enfermedades Digestivas y Metabólicas (ICMDM), Hospital Clínic Barcelona, Barcelona, Spain | 7- Liver Oncology Unit, Liver Unit, ICMDM, Hospital Clínic Barcelona, Barcelona, Spain | 8- Pathology Department, Centro de Diagnóstico Biomédico (CDB), Liver Oncology Unit, Hospital Clínic Barcelona, Barcelona, Spain.

PÓSTER N.º 33

ATF4-Driven Responses Define Prognostic and Immunological Features in Hepatocellular Carcinoma

Stefany Infante Varillas (1) | Eva Santamaria Monasterio (1,2) | Alexander Finnemore (1,3) | Sara Arcelus (1) | Angel M Martínez-Montes (4) | Sergio Barace (1) | Guillermo García Porrero (5) | Nastaransadat Hosseini (1) | Bruno Sangro (2,6,7,8) | Puri Fortes (1,2,7) | Pablo Sarobe (2,4,7) | Juan Bayo (1,9,10) | Josepmaria Argemi (1,2,6,7,8)

1- RNA and DNA Therapy Program. CIMA Universidad de Navarra, Pamplona, Spain | 2- Centro de Investigación Biomedica en Red (CIBER-EHD) | 3- Medical School. University of Navarra, Pamplona, Spain | 4- Immunology Program. CIMA Universidad de Navarra, Pamplona Spain | 5- Northern Health and Social Care Trust, Antrim, Northern Ireland | 6- Cancer Center Clinica Universidad de Navarra, Pamplona-Madrid, Spain | 7- Instituto de Investigación Sanitaria de Navarra (IDISNa), Pamplona, Spain | 8- Liver Unit, Clinica Universidad de Navarra, Pamplona-Madrid, Spain | 9- Hepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral, Pilar, Argentina | 10- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.

MICROAMBIENTE TUMORAL

PÓSTER N.º 34

Platelet C3G enhances hepatocellular carcinoma development associated to fibrosis through regulation of macrophage-liver cell crosstalk

Minerva Iniesta-González (1) | Cristina Baquero (1) | Nerea Palao (1) | Jaime Mancebo (1) | Mateo Cueto-Remacha (1) | Paula Martín-Serna (1) | Paula Linzoain-Agos (1) | Inés de la Guía-Lopez (1) | Álvaro Gutiérrez-Uzquiza (1) | Ángel Cuesta (1) | Paloma Bragado (1) | Carmen Guerrero (2) | Almudena Porras (1)

1- Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Madrid, Spain | 2- Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Universidad de Salamanca-CSIC, Salamanca, Salamanca, Spain.

PÓSTER N.º 35

Regulatory T (Treg) cells depletion ameliorates HCC progression in MASH by restoring anti-tumor innate and adaptive immune responses

Joanna Picó (1,2) | Amalia Tzoumpa (1,2) | Yin Huang (1,2) | Beatriz Lozano-Ruiz (1) | Pedro Zapater (1,2,3,4) | Jose Antonio Gómez Sanchez (1) | Jose Manuel González Navajas (1,2,5)

1- ISABIAL, Alicante | 2- IDiBE, Elche | 3- CIBERehd, Alicante | 4- UMH, San Juan | 5- CIBER, Alicante.

PÓSTER N.º 36 ★ POSTER BLAST ★

The Mosaic of Malignancy: Exploring the Interactions Between Tumor Clones and Stroma in Intrahepatic Cholangiocarcinoma

Claudio Zampato (1) | Paula Cantallops-Vilà (1) | Gemma Garcia-Vicién (1) | Laura Sererols-Viñas (1) | Carmen I. Cárcamo-Giráldez (1) | Marsela Karemani (2) | Roser Pinyol (1) | Manel Esteller (3,4) | Robert F. Schwabe (5) | Anna Moles (1,6) | Josep M. Llovet (1,4,7) | Eduard Porta (3) | Silvia Affò (1)

1- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain | 2- Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain | 3- Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain | 4- Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain | 5- Columbia University, New York, New York, USA | 6- Institut d'Investigacions Biomèdiques de Barcelona (IIBB-CSIC), Barcelona, Spain | 7- Mount Sinai Liver Cancer Program, New York, United States.

PÓSTER N.º 37 ★ POSTER BLAST ★

Proteomic landscape of pediatric and adult liver cancer

Queralt Miñarro-Ribot (1) | Andrea Castaneda (1) | Maria Manuela Barranco (1,2) | Adel Aref (3) | Juanjo Lozano (4) | Rita Alaggio (5) | Maria Torner (6) | Laura Royo (1) | Álvaro del Río-Álvarez (1,2,7) | Lucia Lozano-White (1) | Paola Francalanci (5) | Rudolf Maibach (8) | Madhumita Dandapani (9) | Piotr Czauderna (10) | Margaret Childs (11) | Sophie Branchereau (12) | Bruce Morland (13) | Phil Robinson (3) | Roger Reddel (3) | Carolina Armengol (1,2)

1- Childhood Liver Oncology Group, Germans Trias i Pujol Research Institute (IGTP), Program for Predictive and Personalized Medicine of Cancer (PMPPC), Badalona, Spain | 2- Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBEREHD), Institute of Health Carlos III, 28029 Madrid, Spain | 3- ProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia | 4- CIBEREHD, Bioinformatics platform, CIBEREHD, Institute of Health Carlos III, 28029 Madrid, Spain | 5- Pathology Unit, Department of Diagnostic and Laboratory Medicine, IRCCS Bambino Gesù Children's Hospital, Roma, Italy | 6- Hepatology Unit, Hospital Germans Trias i Pujol, Badalona, Spain | 7- School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain | 8- International Breast Cancer Study Group Coordinating Center, Berne, Switzerland | 9- Childrens Brain Tumour Research Centre, School of Medicine, University of Nottingham, UK. Nottingham University Hospitals NHS Trust, Nottingham, UK | 10- Medical University of Gdansk, Gdansk, Poland | 11- University of Nottingham, Nottingham, UK | 12- Department of Pediatric Surgery, Bicêtre Hospital, AP-HP, Paris-Saclay University, Le Kremlin-Bicêtre, France | 13- Department of Oncology, Birmingham Women's and Children's Hospital, Birmingham, UK.

TECNOLOGÍAS Y -ÓMICAS

PÓSTER N.º 38

Desarrollo de modelos ex vivo para estudiar la respuesta a inmunoterapia en hepatocarcinoma

Carla Castro-Alejos (1) | Diana Llopiz (1,2) | Andrea Moreno (1) | Marta Ruiz (1,2) | Leyre Silva (1,2) | Uxua Mancheño (1,2) | Eduardo Miraval (3) | José Echeveste (3) | Sandra Hervás-Stubbs (1,2,4) | Miguel Sogbe (4,5) | Josepmaria Argemí (2,4,5,6) | Bruno Sangro (2,4,5)

1- Programa de Inmunología e Inmunoterapia, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona | 2- Idisna, Pamplona | 3- Departamento de Anatomía Patológica, Clínica Universidad de Navarra, Pamplona | 4- CIBERehd, Pamplona | 5- Unidad de Hepatología, Clínica Universidad de Navarra, Pamplona | 6- División de Medicina de ADN y ARN, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona.

PÓSTER N.º 39

Prognostic tissue biomarkers for cholangiocarcinoma after tumor resection: from systematic review and meta-analysis to multicenter international validation

Beatriz Val (1,2) | Ainhoa Lapitz (1,2,3) | Tania Pastor (1) | Laura Izquierdo-Sanchez (1,2) | Colm J. O'Rourke (4) | Alejandro Forner (2,5) | Cedric Coulouarn (6) | Cedric Menard (6) | Giovanni Brandi (7) | Simona Tavorlari (7) | Lewis Roberts (8) | Ahmed Fowsiyo (8) | Mohamed Ali (8) | Rocío I. R. Macias (2,9) | Vincenzo Cardinale (10) | Jesper B. Andersen (4) | Adelaida La Casta (11) | Luis Bujanda (1,2,11) | Maria J. Perugorria (1,2,11) | Raúl Jimenez-Aguero (1,2,11) | Jesus M. Banales (1,2,12,13) | Pedro M. Rodrigues (1,2,12)

1- Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), Donostia-San Sebastian, Spain | 2- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), Spain | 3- Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa 48940, Spain | 4- Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark | 5- Barcelona Clinic Liver Cancer (BCLC) group, Liver Unit, Hospital Clínic of Barcelona, Fundació Clínic per a la Recerca Biomèdica (FCRB), IDIBAPS, University of Barcelona,

TECNOLOGÍAS Y -ÓMICAS

Barcelona, Spain | 6- Centre de Lutte contre le Cancer Eugène Marquis, Inserm, Univ Rennes, COSS (Chemistry, Oncogenesis Stress Signaling), UMR_S 1242, 35042 Rennes, France | 7- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy | 8- Department of Medicine, Mayo Clinic, Rochester, MN, USA | 9- Experimental Hepatology and Drug Targeting (HEVEPHARM) group, University of Salamanca, IBSAL, Salamanca, Spain | 10- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy | 11- Departments of Medicine and Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain | 12- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 13- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

PÓSTER N.º 40

Patient-derived hepatoblastoma organoids recapitulate the heterogeneity of the tumor cell compartment

Marc Miravet Martí (1) | Laura Zanatto (2) | Raquel Ferrer-Lorente (1) | Carlos Mateos-Sánchez (1) | Laura Garcia-Tercero (1) | Zhengqing Xu (2) | Maria Mercado-Gómez (1) | Guillermo Serrano | Andrea Castaneda (3) | Maria Manuela Barranco (3,4) | Francisco Hernandez (5) | Laura Guerra (5) | Barbara Torres Guerola (6) | Constantino Sábado (7) | Andres Molino (7) | Gabriela Guillén (7) | Marta Garrido (7) | José Antonio Salinas (8) | Moira Garraus (9) | María Esther Llinares (10) | Carolina Armengol (3,4) | Pau Sancho-Bru (2,4)

1- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. | 2- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Universitat de Barcelona (UB), Barcelona, Spain. | 3- Childhood Liver Oncology Group, Germans Trias i Pujol Research Institute (IGTP), Translational Program in Cancer Research (CARE), Badalona, Spain. | 4- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) | 5- University Hospital La Paz, Pediatric Surgery Department, Madrid, Spain. | 6- University Hospital La Fe, Valencia, Spain. | 7- Hospital Vall d'Hebron, Barcelona, Spain. | 8- Hospital Universitari Son Espases, Palma de Mallorca, Spain. | 9- Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain. | 10- Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.

INFORMACIÓN GENERAL

DIRECTORAS DEL CURSO:

SILVIA AFFÓ (BARCELONA)
MARÍA ARECHEDERRA (PAMPLONA)
MARÍA VARELA (OVIEDO)

SEDE DEL CURSO:

FACULTAD DE CIENCIAS DE LA UNIVERSIDAD DE NAVARRA
Salón de Actos
C. de Irunlarrea, 1
31008 - Pamplona, Navarra

SECRETARÍA TÉCNICA AEEH:



oasis
EVENTS & TRAVEL SOLUTIONS

SECRETARÍA TÉCNICA AEEH

[+34] 91 555 11 19

C/ Sor Ángela de la Cruz, 8
28020 - Madrid - (Spain)

aeeh@viajesoasis.com

www.aeeh.es

FECHAS DEL CURSO:

23 y 24 de octubre de 2025

AGRADECIMIENTOS

La Fundación-Asociación Española para el Estudio del Hígado FEEH-AEEH, agradece muy sinceramente la participación en esta **7.^a Reunión de Hepatología Traslacional** a:



SILVER SPONSOR



BRONZE SPONSOR



GSK

AstraZeneca

teknovas



ciber | EHD

Organizado por:



NOTAS



Organizado por:



Con la colaboración de:



Universidad
de Navarra

oasis
EVENTS & TRAVEL SOLUTIONS

SECRETARÍA TÉCNICA AEEH



[+34] 91 555 11 19
C/ Sor Ángela de la Cruz, 8
28020 - Madrid - (Spain)



aeeh@viajesoasis.com



www.aeeh.es